VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has reached another development milestone in its oncology pipeline. The company announced that its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase and into the next stage of development. This milestone reflects continued progress across the company's therapeutic portfolio as it simultaneously expands the intellectual property supporting its next generation of antibody-based cancer therapies.
The announcement marks the successful completion of the discovery portion of VERAXA's collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz). With the discovery work completed, VERAXA will now focus on building the final therapeutic candidate by combining the antibody binders identified through the collaboration with its own proprietary antibody engineering, linker, and conjugation technologies. Although VXA-222 is not based on VERAXA's BiTAC platform, it leverages these proprietary technologies and represents one of the company's more advanced development programs.
In parallel, VERAXA recently expanded its intellectual property portfolio with its first BiTAC-related patent filings alongside additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted, owned, or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047.
VERAXA continues building a diversified oncology pipeline spanning bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers. The advancement of VXA-222 and the expansion of its patent portfolio underscore VERAXA's commitment to developing innovative therapies and protecting its proprietary technologies.
The news is significant as it highlights VERAXA's progress in the competitive field of antibody-based cancer treatments. The successful completion of the discovery phase with OmniAb and the subsequent advancement of VXA-222 could potentially lead to new therapeutic options for patients with difficult-to-treat cancers. Moreover, the strengthened patent portfolio provides a solid foundation for the company's future growth and positions it well in the marketplace.
Investors and stakeholders can access the latest news and updates relating to VRXA in the company's newsroom at https://nnw.fm/VRXA.
